Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase-Reference-Cited by-同舟云学术

Amyotrophic lateral sclerosis associated with homozygosity for an Asp90Ala mutation in CuZn-superoxide dismutase

Published:1995-05 Issue:1 Volume:10 Page:61-66
ISSN:1061-4036
Container-title:Nature Genetics
language:en
Short-container-title:Nat Genet

Author:

Andersen Peter M.,Nilsson Peter,Ala-Hurula Veli,Keränen Marja-Leena,Tarvainen Ilkka,Haltia Tuula,Nilsson Lotta,Binzer Michael,Forsgren Lars,Marklund Stefan L.

Publisher

Springer Science and Business Media LLC

Subject

Genetics

Link

http://www.nature.com/articles/ng0595-61.pdf

Reference39 articles.

1. Tandan, R. & Bradley, W.G. Amyotrophic lateral sclerosis Part 1. Clinical features, pathology, and ethical issues in management. Ann. Neurol. 18, 271–280 (1985).

2. Rosen, D.R. et al. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis. Nature 362, 59–62 (1993).

3. Ogasawara, M. et al. Mild ALS in Japan associated with novel SOD mutation. Nature Genet 5, 323–324 (1993).

4. Rainero, I. et al. SOD1 missense mutation in an Italian family with ALS. Neurology 44, 347–349 (1994).

5. Elshafey, A., Lanyon, W.O. & Conner, J.M. Identification of a new missense point mutation in exon 4 of the Cu/Zn superoxide dismutase gene in a family with amyotrophic lateral sclerosis. Hum. molec. Genet. 3, 363–364 (1994).

Cited by 283 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOD1 gene screening in ALS – frequency of mutations, patients’ attitudes to genetic information and transition to tofersen treatment in a multi-center program;Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration;2024-09-13

2. Epigenetics in the formation of pathological aggregates in amyotrophic lateral sclerosis;Frontiers in Molecular Neuroscience;2024-09-03

3. Tofersen decreases neurofilament levels supporting the pathogenesis of the SOD1 p.D91A variant in amyotrophic lateral sclerosis patients;Communications Medicine;2024-07-25

4. Clinical and patient‐reported outcomes and neurofilament response during tofersen treatment in SOD1‐related ALS—A multicenter observational study over 18 months;Muscle & Nerve;2024-06-20

5. SOD1 Enzymatic Activity in CSF from ALS patients with and withoutSOD1mutations;2024-06-16